BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24641245)

  • 1. A specific DNA methylation profile correlates with a high risk of disease progression in stage I classical (Alibert-Bazin type) mycosis fungoides.
    Ferrara G; Pancione M; Votino C; Quaglino P; Tomasini C; Santucci M; Pimpinelli N; Cusano F; Sabatino L; Colantuoni V
    Br J Dermatol; 2014 Jun; 170(6):1266-75. PubMed ID: 24641245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.
    Ralfkiaer U; Lindahl LM; Litman T; Gjerdrum LM; Ahler CB; Gniadecki R; Marstrand T; Fredholm S; Iversen L; Wasik MA; Bonefeld CM; Geisler C; Krejsgaard T; Glue C; Røpke MA; Woetmann A; Skov L; Grønbæk K; Odum N
    Anticancer Res; 2014 Dec; 34(12):7207-17. PubMed ID: 25503151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
    Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
    Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
    Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
    Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides.
    Navas IC; Ortiz-Romero PL; Villuendas R; Martínez P; García C; Gómez E; Rodriguez JL; García D; Vanaclocha F; Iglesias L; Piris MA; Algara P
    Am J Pathol; 2000 May; 156(5):1565-72. PubMed ID: 10793068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas.
    Quaglino P; Pimpinelli N; Berti E; Calzavara-Pinton P; Alfonso Lombardo G; Rupoli S; Alaibac M; Bottoni U; Carbone A; Fava P; Fimiani M; Mamusa AM; Titli S; Zinzani PL; Bernengo MG;
    Cancer; 2012 Dec; 118(23):5830-9. PubMed ID: 22674564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides.
    de Masson A; O'Malley JT; Elco CP; Garcia SS; Divito SJ; Lowry EL; Tawa M; Fisher DC; Devlin PM; Teague JE; Leboeuf NR; Kirsch IR; Robins H; Clark RA; Kupper TS
    Sci Transl Med; 2018 May; 10(440):. PubMed ID: 29743350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycosis fungoides.
    Zinzani PL; Ferreri AJ; Cerroni L
    Crit Rev Oncol Hematol; 2008 Feb; 65(2):172-82. PubMed ID: 17950613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
    Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
    J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
    Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
    Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
    Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
    Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression dynamics of CXCL12 and CXCR4 during the progression of mycosis fungoides.
    Daggett RN; Kurata M; Abe S; Onishi I; Miura K; Sawada Y; Tanizawa T; Kitagawa M
    Br J Dermatol; 2014 Oct; 171(4):722-31. PubMed ID: 24725174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel biomarkers, dysregulated epigenetics, and therapy in cutaneous T-cell lymphoma.
    Wong HK
    Discov Med; 2013 Sep; 16(87):71-8. PubMed ID: 23998443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
    Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
    Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways.
    Wozniak MB; Tracey L; Ortiz-Romero PL; Montes S; Alvarez M; Fraga J; Fernández Herrera J; Vidal S; Rodriguez-Peralto JL; Piris MA; Villuendas Deceased R
    Br J Dermatol; 2009 Jan; 160(1):92-102. PubMed ID: 18945306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycosis fungoides: association of KIR ligands and HLA-DQB1*05 with bad prognosis of the disease.
    Brazzelli V; Rivetti N; Badulli C; Carugno A; Cananzi R; De Silvestri A; Martinetti M; Borroni G
    J Eur Acad Dermatol Venereol; 2016 Feb; 30(2):266-9. PubMed ID: 25753140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transformed mycosis fungoides: clinicopathological features and outcome.
    Barberio E; Thomas L; Skowron F; Balme B; Dalle S
    Br J Dermatol; 2007 Aug; 157(2):284-9. PubMed ID: 17573879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma.
    Gerami P; Rosen S; Kuzel T; Boone SL; Guitart J
    Arch Dermatol; 2008 Jun; 144(6):738-46. PubMed ID: 18559762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.